23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change today | 1-month return | 1-year return | Total return |
---|---|---|---|---|
The fight against COVID19 | - | - | - | - |
^GSPC | +1.03% | -0.42% | +25.20% | +5470.69% |
Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 148.58 | -0.69 | -0.46% | 4:00 pm GMT-4 | 4.91M | 7.68M | 357.58B |
ABBV | AbbVie Inc. | 162.73 | -1.06 | -0.65% | 4:03 pm GMT-4 | 5.73M | 5.69M | 287.36B |
PFE | Pfizer Inc. | 28.16 | +0.35 | +1.26% | 4:00 pm GMT-4 | 52.13M | 41.56M | 159.46B |
SNY | Sanofi | 49.33 | +0.32 | +0.65% | 4:00 pm GMT-4 | 1.19M | 2.09M | 123.15B |
REGN | Regeneron Pharmaceuticals, Inc. | 958.64 | +1.64 | +0.17% | 4:00 pm GMT-4 | 344.33k | 470.72k | 105.63B |
GSK | GSK plc | 43.45 | -0.05 | -0.11% | 4:00 pm GMT-4 | 2.02M | 3.38M | 88.65B |
GILD | Gilead Sciences, Inc. | 65.54 | +0.76 | +1.17% | 4:00 pm GMT-4 | 7.06M | 7.32M | 81.73B |
MRNA | Moderna, Inc. | 122.13 | -2.87 | -2.30% | 4:00 pm GMT-4 | 3.94M | 3.99M | 46.81B |
TAK | Takeda Pharmaceutical Company Limited | 13.36 | -0.01 | -0.07% | 4:00 pm GMT-4 | 1.58M | 1.63M | 42.13B |
BNTX | BioNTech SE | 93.35 | +0.63 | +0.68% | 4:00 pm GMT-4 | 1.09M | 598.83k | 22.50B |
VIR | Vir Biotechnology, Inc. | 10.22 | -0.17 | -1.64% | 4:00 pm GMT-4 | 1.18M | 1.04M | 1.39B |
NVAX | Novavax, Inc. | 4.76 | -0.17 | -3.45% | 4:00 pm GMT-4 | 4.78M | 6.97M | 668.32M |
INO | Inovio Pharmaceuticals, Inc. | 11.88 | -0.22 | -1.82% | 4:00 pm GMT-4 | 260.97k | 473.22k | 307.77M |
Insightful Analysis of Shockwave Medical's Position in the Cardiovascular Device Market
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.